OncoTargets and Therapy · 2014 · 15 citations · 39 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaThoracic OncologyCancer BiomarkersCancer Molecular PathologyLung CancerMalignant NeoplasmsTumor AntigensTumor MarkersAdenocarcinoma PathologyClinicopathologic FeaturesLung AdenocarcinomaLung Cancer PathologyProtein Expression BiomarkersThymidine Nucleotide MetabolismThymidylate Synthesis
The aim of the present study was to investigate the clinicopathologic/prognostic significance of thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP) proteins in postoperative non-small cell lung cancer (NSCLC) patients. Microarray slides from a set of 178 NSCLC patients were used for the detection of TS, OPRT, and TP expression by immunohistochemistry. The correlation between clinicopathologic factors and protein expression of three proteins was analyzed. Ninety seven carcinomas (57.4%) were TS-positive, 90 carcinomas (53.9%) were OPRT-positive, and 102 carcinomas (69.4%) were TP-positive. Compared with the TS-positive patients, the overall survival (OS) was significantly lower in the TS-negative patients (hazard ratio [HR] =1.766, 95% confidence interval [CI] =1.212-2.573, P=0.003). Significant differences between TS-positive and TS-negative patients was also observed in the following stratified analyses: 1) adenocarcinoma subgroup (HR =2.079, 95% CI =1.235-3.500, P=0.006); 2) less than 60-year-old subgroup (HR =1.890, 95% CI =1.061-3.366, P=0.031); 3) stage II/III subgroup (HR =1.594, 95% CI =1.036-2.453, P=0.034); and 4) surgery plus adjuvant therapy subgroup (HR =1.976, 95% CI =1.226-3.185, P=0.005). However, the OS was not significantly correlated with OPRT or TP protein expression. This study demonstrates that the TS level in tumor tissues may be a useful marker to predict the postoperative OS in NSCLC patients.
39
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Juha Kononen, Lukas Bubendorf, Anne Kallionimeni et al. · Nature Medicine · 1998 · 4.1K citations
Gary M. Strauss, James E. Herndon, Michael A. Maddaus et al. · Journal of Clinical Oncology · 2008 · 990 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
DNA Synthesis and Repair Genes <i>RRM1</i> and <i>ERCC1</i> in Lung Cancer
Zhong Zheng, Tingan Chen, Xueli Li et al. · New England Journal of Medicine · 2007 · 467 citations · Full text
McCarty Ks, Éva Szabó, Flowers Jl et al. · PubMed · 1986 · 422 citations
Medicine, Endocrinology, Oncology +17